Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment

J Cardiol. 2017 May;69(5):774-778. doi: 10.1016/j.jjcc.2016.07.009. Epub 2016 Aug 25.

Abstract

Background: We aimed to investigate the effects of immunosuppressive and biological agents on refractory Takayasu arteritis (TA) patients resistant to or dependent on glucocorticoids.

Methods: Forty-four consecutive TA patients were enrolled, and the clinical characteristics and effectiveness of the immunosuppressive and biological agents in achieving and maintaining remission among glucocorticoid-resistant or glucocorticoid-dependent patients were investigated.

Results: Fifteen patients showed favorable response to the initial glucocorticoid treatment, and 29 patients exhibited resistance to initial glucocorticoid treatment or relapsed with tapering glucocorticoid. Of the 29 patients, 5 responded to additional glucocorticoid treatment, and 22 of the remaining 24 glucocorticoid-resistant or glucocorticoid-dependent patients were prescribed immunosuppressive agents. Methotrexate was the most commonly used in these patients as the first-line treatment. In total, 10 patients maintained remission using immunosuppressive agents, with the effectiveness of each agent about 20%. The only significant difference between patients who were and were not able to achieve and maintain remission with immunosuppressive agents was the presence of the HLA-B52 allele (p<0.0001). Biological agents were administered to 6 patients refractory to immunosuppressive agents. All patients were administered tumor necrosis factor (TNF) inhibitors as the first-line treatment, and 3 patients maintained remission. Anti-interleukin-6 receptor antibody was administered to 2 patients who were resistant to the TNF inhibitors, and 1 patient achieved and maintained remission.

Conclusion: In our cohort, 64% of the glucocorticoid-resistant or glucocorticoid-dependent patients maintained remission through a combined treatment with glucocorticoid, immunosuppressive agents, and/or biological agents. The combined use of immunosuppressive and biological agents appears to be a promising treatment option for achieving and maintaining remission in refractory TA patients.

Keywords: Biological agent; Immunosuppressive agents; Relapse; Takayasu arteritis.

MeSH terms

  • Adult
  • Alleles
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Drug Resistance
  • Drug Therapy, Combination
  • Etanercept / therapeutic use
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • HLA-B52 Antigen / genetics
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Infliximab / therapeutic use
  • Male
  • Prednisolone / administration & dosage
  • Prednisolone / adverse effects
  • Remission Induction
  • Retrospective Studies
  • Takayasu Arteritis / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • HLA-B52 Antigen
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Prednisolone
  • Infliximab
  • tocilizumab
  • Etanercept